GlaxoSmithKline (LON:GSK) posted its earnings results on Wednesday. The company reported GBX 24.60 ($0.34) earnings per share for the quarter, beating the Zacks’ consensus estimate of GBX 24.30 ($0.34) by GBX 0.30 ($0.00), Bloomberg Earnings reports. GlaxoSmithKline had a return on equity of 348.10% and a net margin of 9.36%.
LON:GSK traded up GBX 24.60 ($0.34) during trading hours on Thursday, reaching GBX 1,436.80 ($20.04). The stock had a trading volume of 8,498,186 shares, compared to its average volume of 9,120,000. GlaxoSmithKline has a 12-month low of GBX 1,235.20 ($17.23) and a 12-month high of GBX 1,724.50 ($24.05).
The company also recently announced a dividend, which will be paid on Thursday, July 12th. Shareholders of record on Thursday, May 10th will be given a GBX 19 ($0.26) dividend. This represents a yield of 1.35%. The ex-dividend date of this dividend is Thursday, May 10th.
In other GlaxoSmithKline news, insider Patrick Vallance sold 14,022 shares of the firm’s stock in a transaction on Monday, February 19th. The stock was sold at an average price of GBX 1,318 ($18.38), for a total value of £184,809.96 ($257,754.48). Also, insider Philip R. Hampton bought 3,028 shares of the firm’s stock in a transaction on Wednesday, April 25th. The stock was purchased at an average cost of GBX 1,445 ($20.15) per share, with a total value of £43,754.60 ($61,024.55). Over the last three months, insiders acquired 3,617 shares of company stock valued at $5,130,288 and sold 23,765 shares valued at $31,152,709.
GlaxoSmithKline Company Profile
GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines.
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.